Depressants in 2026: The Drug Class Without a Modern Playbook

The depressants category — benzodiazepines, Z-drugs (zolpidem, eszopiclone), kratom-derived 7-OH, and an expanding gray-market group of GABA-active novel compounds — does not have a clean public narrative. It doesn’t have a CDC death tally that updates monthly. It doesn’t have its own FDA approval calendar like nicotine or psychedelics. It does have an aging prescribing footprint, a deprescribing science that has improved meaningfully in the past two years, and a treatment-system response that has not.

The lens: what changed in the science (and what didn’t)

The biggest movement in the depressant class in 2025–2026 happened in deprescribing. A new joint clinical practice guideline (Supporting Patients Through Benzodiazepine Tapering, 2024–2025) consolidated what addiction medicine and primary care had been moving toward separately: tapers should start gradual (20–25% reduction, held 2–4 weeks), then slow further (5–12.5%), with the patient choosing the pace. The American Society of Addiction Medicine’s benzodiazepine tapering guidance and a 2024 eClinicalMedicine international scoping review align: forced tapers are not recommended except for narrow medical reasons (significant respiratory compromise being the main one).

What hasn’t changed: there is still no FDA-approved pharmacotherapy for benzodiazepine use disorder. There is no equivalent to buprenorphine for the patient who has been on alprazolam for fifteen years and wants out. The first-line treatment is a slow taper, with cognitive behavioral therapy for the conditions that drove the prescription in the first place — anxiety, insomnia, panic. The treatment system that exists for opioid use disorder, with structured MAT, induction protocols, and reimbursement codes, does not have a parallel for BZDs.

This matters because BZDs and Z-drugs continue to be prescribed at scale. Guidelines suggest short-term use only (under four weeks), but real-world prescribing patterns show long-tail continuation — particularly among older adults, who are also the population most vulnerable to withdrawal complications, falls, and cognitive side effects.

The 7-OH question

Layered on top of the prescription-depressant landscape is a fast-moving regulatory story around kratom. Kratom itself — the plant, Mitragyna speciosa — is unscheduled at the federal level. But 7-hydroxymitragynine (7-OH), one of kratom’s minor alkaloids (less than 2% of the natural leaf’s alkaloid content), has been the focus of FDA action. In June 2025, the FDA issued warning letters to seven companies marketing concentrated 7-OH products. In July 2025, the FDA formally recommended DEA schedule synthetic concentrated 7-OH as Schedule I — a process that, as of this morning, is still working through DEA rulemaking.

What’s clinically true: 7-OH is a partial mu-opioid agonist. Concentrated products amplify that effect substantially beyond what natural kratom leaf produces. People using concentrated 7-OH for pain or opioid-replacement purposes can experience opioid-like physical dependence and withdrawal — including a presentation that mimics, but is distinct from, traditional opioid withdrawal.

The treatment-system implication: people stabilizing off 7-OH benefit from protocols that look like opioid taper management, often with buprenorphine. But because kratom (and by extension 7-OH) is still legally ambiguous, many primary-care providers don’t ask about it, and many patients don’t volunteer it. The clinical picture only becomes clear when a withdrawal syndrome doesn’t match the disclosed history.

Where the evidence is actively moving

Three things to watch over the next 6–12 months: DEA action on 7-OH scheduling (the rule is drafted but not finalized); state-level moves on kratom regulation, which have been highly variable and tend to act ahead of federal frameworks; and continued refinement of slow-taper protocols for BZDs, including better outpatient infrastructure to deliver them. The clinical-practice question that doesn’t have a good answer yet is how to integrate the new tapering science into health-system workflows that still reflexively route benzo cases to inpatient detox — which can be appropriate but is rarely the only option.

Where the field disagrees

Reasonable clinicians disagree on whether kratom (the leaf, not concentrated 7-OH) should be considered for opioid-replacement purposes in low-resource settings. The American Society of Addiction Medicine’s official position is cautious; some harm-reduction practitioners take a more pragmatic stance. The 2025–2026 FDA actions don’t resolve this — they specifically target concentrated 7-OH, not natural kratom — but they reshape the gray-market environment in ways that ripple into the harm-reduction discussion.

The American Society of Addiction Medicine’s official position is cautious; some harm-reduction practitioners take a more pragmatic stance.

Why this matters for people in recovery

If you’re tapering off a benzodiazepine, the most important thing the 2025–2026 guidelines emphasize is that the pace belongs to you and your prescriber together — not to a calendar imposed by an insurance authorization. Slow tapers work better than fast ones; the data is clearer on this than it has been in a decade.

If you’re using kratom or a concentrated 7-OH product and considering stopping, talk to a prescriber who knows the difference between the two. The withdrawal pattern matters for treatment selection. The SAMHSA Treatment Locator lists facilities by SUD type, and Arizona’s AHCCCS member services can route you to in-network options. If you’re in immediate distress, 988 is the crisis line.

The depressant class is, in 2026, the part of the SUD landscape that has the least clean public framing — and the most catching up to do.